ReviewEuropean journal of nuclear medicine and molecular imaging2012
Radiolabelled RGD peptides for imaging and therapy.
Review in European journal of nuclear medicine and molecular imaging, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 95 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
95 citing papers in PubMed.
- A peptide nucleic acid-based pretargeting approach usingEJNMMI research · 2026Article
- EGFR- and Integrin αInternational journal of molecular sciences · 2024Review
- RGD peptide in cancer targeting: Benefits, challenges, solutions, and possible integrin-RGD interactions.Cancer medicine · 2024Review
- Peptide-Based Agents for Cancer Treatment: Current Applications and Future Directions.International journal of molecular sciences · 2023Review
- Cyclic Ruthenium-Peptide Conjugates as Integrin-Targeting Phototherapeutic Prodrugs for the Treatment of Brain Tumors.Journal of the American Chemical Society · 2023Article
- Peptides for trans-blood-brain barrier delivery.Journal of labelled compounds & radiopharmaceuticals · 2023Review
- Bioorthogonal PROTAC Prodrugs Enabled by On-Target Activation.Journal of the American Chemical Society · 2023Article
- A Chemical Strategy for the Preparation of Multimodified Peptide Imaging Probes.The Journal of organic chemistry · 2023Article
- Theranostics with photodynamic therapy for personalized medicine: to see and to treat.Theranostics · 2023Review
- RGD Forever!-Past, Present, and Future of a 3-Letter-Code in Radiopharmacy and Life Sciences.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Potential of Nuclear Imaging Techniques to Study the Oral Delivery of Peptides.Pharmaceutics · 2022Review
- A Dimeric FAP-Targeting Small-Molecule Radioconjugate with High and Prolonged Tumor Uptake.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022Article
- Radionuclide imaging and therapy directed towards the tumor microenvironment: a multi-cancer approach for personalized medicine.European journal of nuclear medicine and molecular imaging · 2022Review
- Palmitic Acid-Conjugated Radiopharmaceutical for Integrin αPharmaceutics · 2022Article
- Nano-Theranostics for the Sensing, Imaging and Therapy of Prostate Cancers.Frontiers in chemistry · 2022Review
- Review
- It's Time to Shift the Paradigm: Translation and Clinical Application of Non-αvβ3 Integrin Targeting Radiopharmaceuticals.Cancers · 2021Review
- Integrins regulate stemness in solid tumor: an emerging therapeutic target.Journal of hematology & oncology · 2021Review
- There is a world beyond αvβ3-integrin: Multimeric ligands for imaging of the integrin subtypes αvβ6, αvβ8, αvβ3, and α5β1 by positron emission tomography.EJNMMI research · 2021Review
- [International journal of molecular sciences · 2021Article
35 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Imaging of angiogenesis has become increasingly important with the rising use of targeted antiangiogenic therapies like bevacizumab (Avastin). Non-invasive assessment of angiogenic activity is in this respect interesting, e.g. for response assessment of such targeted antiangiogenic therapies. One promising approach of angiogenesis imaging is imaging of specific molecular markers of the angiogenic cascade like the integrin α(v)β(3). For molecular imaging of integrin expression, the use of radiolabelled peptides is still the only approach that has been successfully translated into the clinic. In this review we will summarize the current data on imaging of α(v)β(3) expression using radiolabelled RGD peptides with a focus on tracers already in clinical use. A perspective will be presented on the future clinical use of radiolabelled RGD peptides including an outlook on potential applications for radionuclide therapy.
Indexed as
Identifiers
22388629What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.